The CD4+/CD8+ ratio crucially determines tumor patients' cellular immune function, with an increased ratio indicating dominant positive immune response regulation, while a decreased or less than 1 ratio suggests impaired cellular immune function. The gene discussed is CD8A; the disease is neoplasm.